Source: Eur Respir J 2006; 27: 460-469
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Idali F., Wiken M., Wahlstrom J., Mellstedt H., Eklund A., Rabbani H., Grunewald J., Nagano J. , Iyonaga K. , Kawamura K. , Yamashita A. , Ichiyasu H. , Okamoto T. , Suga M. , Sasaki Y. , Kohrogi H. . Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis . Eur Respir J 2006; 27: 460-469

Member's Comments

No comment yet.

Related content which might interest you: The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2002; 19: 1124-1127 Year: 2002 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 The JAK3 inhibitor CP-690550 is a potent anti-fibrosis agent in a murine model of pulmonary fibrosis induced by bleomycin Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Source: Eur Respir J 2007; 29: 976-985 Year: 2007 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Therapeutic pamrevlumab (FG-3019) is more effective than pirfenidone or nintedanib in a mouse radiation-induced lung fibrosis model Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2005; 25: 708-714 Year: 2005 Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats Source: Eur Respir J 2001; 17: 1228-1235 Year: 2001 Role of anti-proliferative therapy in PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Bleomycin induced lung fibrosis in mice is attenuated by a new somatostatin analog Source: Annual Congress 2006 - Matrix remodelling at the interface of lung fibrosis and emphysema Year: 2006 Erythropoietin (EPO) inhibits the bleomycin (BLM)-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Emerging mechanisms in lung injury Year: 2010 Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013